References
- Roedel C, Becker H, Fietkau R, Graeven U, Hohenberger W, Hothorn T, . Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First result of German CAO/ARO/AIO- 04 randomized phase III trial. J Clin Oncol 2011;29 (Suppl; abstr LBA3505).
- Roh MS, Yothers GA, O’Connell MJ, Beart RW, Pitot HC, Shields AF, . The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. J Clin Oncol 2011(Suppl; abstr 3503).
- Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne P-L, . Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2011;28: 1638–44.
- Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, . Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011;29:2773–80.
- Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Late adverse effects of radiation therapy for rectal cancer – a systematic overview. Acta Oncol 2007;46:504–16.
- Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H. Venous thromboembolism in patients with colorectal cancer: Incidence and effect on survival. J Clin Oncol 2006;24: 1112–8.
- Connolly GC, Khorana AA. Emerging risk stratification approaches to cancer-associated thrombosis: Risk factors, biomarkers and a risk score. Thromb Res 2010;125 (Suppl 2):S1–7.
- Starling N, Rao S, Cunningham D, Iveson T, Coxon F, Middleton G, . Thromboembolism in patients with advanced gastroesophageal cancer treated with Anthracynin, Platinum, and Fluoropyrimidine combination chemotherapy: A report from National Cancer Research Institute Upper Gastrointestinal Clinical Group. J Clin Oncol 2009; 27:3786–93.
- Heit JA. Cancer and venous thromboembolism: Scope of the problem. Cancer Control 2005;12(Suppl 1)5–10.
- Abdel-Razeq HN, Mansour AH, Ismael YM. Incidental pulmonary embolism in cancer patients: Clinical characteristics and outcome – a comprehensive cancer center experience. Vasc Health Risk Manag 2011;7:153–8.
- Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555–68.
- Chau I, Brown G, Cunningham D, Tait D, Wotherspoon A, Norman AR, . Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging – defined poor-risk rectal cancer. J Clin Oncol 2006;24:668–74.
- Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, . Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006;24: 4983–90.
- Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111:4902–7.